The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA ...

Amgen sign on company building At the other end of the spectrum is biotech behemoth Amgen (NASDAQ:AMGN).It owns a large portfolio of billion-dollar drugs producing revenue of $8.4 billion in the ...

As of November 2023, popular biotech ETFs include: When investing in biotech, investors not only consider earnings or revenue but also the potential for Food and Drug Administration (FDA ...

Goodbye, seasonal affective disorder. How is that possible? I don’t know, it just is. The black mood in biotech investing that I described just a few weeks ago has, somehow, worsened.

Strong financial positions reduce risk in biotech investing, prioritizing firms with both current and pipeline drugs. Vertex shows diversified drug development in chronic diseases, underscoring ...

When you invest in biotech penny stocks, you’ll typically invest in stocks in one of three categories. Those include preclinical, clinical, and commercial-phase companies. Ocean Biomedical ...

The leading index fund of biotechnology stocks (XBI) has lost more than 60% of its value from its peak in February of 2021. This has negatively impacted investor returns and stalled investment ...

Analyst David Toung says Iqvia's business model is relatively resistant to short-term market shocks, potentially making it an excellent defensive biotech investment. Toung says Iqvia has ...

"Instead of being beholden to the binary nature of biotech events, investing in a broader pool of biotech firms helps hedge risk for negative events while still having significant exposure to long ...

Set against a backdrop of barren biotech investment, Vivo Capital has secured $740m to back preclinical and clinical-stage life science companies. The funds will be allocated in the latest cycle ...

The sector, represented by the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB), which seeks investment results that correspond generally to the price and yield performance of the NASDAQ ...